The war against counterfeit medicine my story

The War Against Counterfeit Medicine My Story

Volumn , Issue , 2011, Pages 1-437

  Akunyili, Dora Nkem ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84947301714     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (58)

1. “The Pharmaceutical Industry In Nigeria: Historical Review, Problems And Expectations”, unpublished paper of the Pharmaceutical Manufacturers Group Of Manufacturers Association Of Nigeria (PMG–MAN), 2003.
2. Black’s Law Dictionary, 5thedn, St. Paul, MN: West Publishing Co., 1979.
3. “Counterfeit Drugs: Guidelines to develop measures to combat counterfeitdrugs”, WHO/EDM/QSM 99.1, 1999, at:http://whqlibdoc.who.int/hq/1999/WHO_EDM_QSM_99.1.pdf.
4. “The Federal Food, Drugs And Cosmetic Act, Subchapter II”, reproduced inthe United States Pharmacopoeia, USP23, Rockville, MD: United StatesPharmacopoeia Convention, Inc., 1995.
5. International Pharmaceutical Federation (FIP), ”Statement of Policy onCounterfeitMedicines”, 2003, at:www.fip.org.
6. Pakistan Manual of Drug Laws, Lahore Times Publication, 1987.
7. Republic Act No. 8203, Republic of the Philippines, Congress of the Philippines, 22 July 1996.
8. Supplement To Official Gazette ExtraordinaryNo. 3 Vol. 80, 20th February 1993, Abuja, Nigeria: Federal Ministry Of Health.
9. Supplement To Official Gazette Extraordinary No. 2. Vol. 80, 20th February, 1993, Abuja, Nigeria: Federal Ministry Of Health.
10. Deadly Price” (“Silent Killer”) of the Canadian television documentary seriesMayday (Air Crash Investigations, Air Emergency). http://en.wikipedia.org/wiki/Partnair_Flight_394
11. Dunbar, A., “Dealing With Counterfeiting And Tampering: A Primer On ChoosingSecurity Labels”, at: www.security-int.com/Article.Asp.
12. Hopkins, D.et al., Counterfeiting Exposed. Protecting Your Brand And Customers, Hoboken, NJ: John Wiley & Sons, 2003.
13. The War Against Counterfeit Medicine
14. “The Rational Use of Drugs: WHO Report of the Conference of Experts”, November 1985, Nairobi, Kenya.
15. World Health Organization, Fact Sheet no. 275, “Substandard and Counterfeit Medicines”, 2003.
16. IMPACT (November 2006),”Counterfeit Medicines: An Update on Estimates”, at: www.who.int/medicines/services/counterfeit/impact/TheNewEstimatesCounterfeit.pdf.
17. “Counterfeit And Substandard Drugs In Myanmar And Vietnam”, Report of astudy carried out in cooperation with the Governments of Myanmar and VietNam, EDN Research Series No. 29, 1999, at:http://apps.who.int/medicinedocs/en/d/Js2276e/8.html.
18. World Health Organization, Fact Sheet no. 275, “Substandard and Counterfeit Medicines”, 2003.
19. Honigsbaum, M., The Fever Trail, New York: Farrar, Straus & Giroux, 2002.
20. Norris, G., “Protecting Pharmaceutical Intellectual Property Rights –CounterfeitingTrends in Asia”, Proceedings of the Global Forum on Pharmaceutical Anti-Counterfeiting,2002, Geneva, Switzerland, Egham, UK: Reconnaissance International, 2002.
21. Tatako, M., ”Mission Report: Socialist Republic Of Viet Nam”, WHO RegionalOffice For The Western Pacific, 1992.
22. World Health Organization, Fact Sheet no. 275, “Substandard and Counterfeit Medicines”, 2003.
23. Newton, Paul N., ”Murder By Fake Drugs In SE Asia – Prevalence AndPrevention”, Proceedings of the Global Forum on Pharmaceutical Anti-Counterfeiting, 2002, Geneva, Switzerland, Egham, UK: Reconnaissance International, 2002.
24. Myanmar Information Committee, Yangon Information Sheet No. C- 2891 (I) 3rd January, 2004._ _Future Plans/Work in Progress Recommendations and Conclusion 309
25. “Counterfeit And Substandard Drugs In Myanmar And Vietnam”, Report of astudy carried out in cooperation with the Governments of Myanmar and VietNam, EDN Research Series No. 29, 1999, at:http://apps.who.int/medicinedocs/en/d/Js2276e/8.html.
26. Unpublished report of Project Philicap, April 1995, at:http://apps.who.int/medicinedocs/en/d/Js2276e/6.2.html.
27. Cockburn, R., “Crime, Fear and Silence: Making Public the Fake Pharmaceutical Drug Racket”, Proceedings of the Global Forum on Pharmaceutical Anti-Counterfeiting, 2002, Geneva, Switzerland, Egham, UK: Reconnaissance International, 2002.
28. Clarke, S., ”Investigation of Counterfeit Medicinal Products in the UnitedKingdom”, Proceedings of the Global Forum on Pharmaceutical Anti-Counterfeiting, 2002, Geneva, Switzerland, Egham, UK: Reconnaissance International, 2002.
29. Pakharenko-Anderson, A., “Building Legislation and RegulatoryImplementation Environment: the Ukraine Experience”, Proceedings of theGlobal Forum on Pharmaceutical Anti-Counterfeiting, 2002, Geneva, Switzerland, Egham, UK: Reconnaissance International, 2002.
30. Rosen, R., “Fighting Counterfeit Drugs in Russia: A Case Study”, Proceedings of the Global Forum on Pharmaceutical Anti-Counterfeiting, 2002, Geneva, Switzerland, Egham, UK: Reconnaissance International, 2002.
31. Van Suchtelen, J.P., ”Counterfeit Pharmaceuticals”, Proceedings of the SMI Conferenceon‘Securing the Pharmaceutical Chain’ 29th–30th November 2004, 2005.
32. “Safeguarding the integrity of the medicines supply chain in Europe”, at:www.safemedicines.org/resources/documents/Pfizercftwo-pager.pdf.
33. Jaret, P., Los Angeles Times, February 9, 2004.
34. “Heparin Contamination May Have Been Deliberate, F.D.A. Says”, at:www.nytimes.com/2008/04/30/health/policy/30heparin.html.310 The War Against Counterfeit Medicine
35. Bernstein, I.B.G., ”Pedigree Update: RFID and Diversion – USFDA”, at:www.nabp.net/ftpfiles/AM/104/Pedigreeupdate.pdf.
36. WHO: Essential Drug Monitor, double issue No. 28 & 29, 2000.
37. Action Programme on Essential Drugs, WHO/DAP 95.3, Geneva: WHO, 1995.
38. Goodman, P.S., Washington Post Foreign Service August 30, 2002.
39. Scientific Committee on Consumer Product SCCP/1181/08 2008, Opinion onDiethylene glycol, European Commission – Health & Consumer Protection, at:http://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_139.pdf.
40. “Counterfeit Kills: Nurses Target Counterfeit Medicines”, Information andAction tool kit, Proceedings of the May 2005 Inter national Nurses Day (Geneva, Switzerland), International Council of Nurses, 2005.
41. Poole, D., ed., “Drug Distribution and Fake Drugs in Nigeria”, International Workshop, Lagos, Nigeria, 1989.
42. Ochekpe, N.A. et al., “An Assessment of the Compliance of Some Essential Drugsin Nigeria to Pharmacopoeial Specifications”, Journal of Pharmacy and Bioresources, Vol. 3, No. 1, 2006, pp. 7–11.
43. Taylor, R.B. et al., The Lancet 357(9272), 2001, pp. 1933–6.
44. Iacocca, L. and WilliamNovak, IACOCCA, An Autobiography, Bantam, 1984.
45. The New Webster’s Dictionary of the English Language, International Edition.
46. Babalola, A., “Federal Government’s Anti Corruption Crusade: The WorthyExample of National Agency for Food and Drug Administration and Control(NAFDAC)”, 2002.
47. “Counterfeit Dr ugs: Guidelines for the Development of Measures toCombat Counterfeit Drugs”, WHO, 1999, p. 16._ _Future Plans/Work in Progress Recommendations and Conclusion 311
48. Adinuba, D.C., “NAFDAC as a Study in Management”, Daily Sun, December 15,2003.
49. Babatunde, O., “Pharmaceutical Manufacturers Scale Dumping Hurdle, ReturntoProfitability”, The Guardian, September 21, 2001.
50. Chukwuma, M., “Pharmaceutical Firm Realises 2.62 Billion Naira from KeyProducts”, The Guardian, January 29, 2003.
51. Adeoye, L., “Pharma Deko Embarks on Capacity Expansion – 60% of Goods inNigeria Smuggled”, The Punch, September 17, 2003.
52. Egene, G., “Pharma Deko Pays Dividend After 4 Years”, The Punch, September 19, 2003.
53. Anon, The Nigerian Tribune, September 17, 2003.
54. Anon, Vanguard, January 22, 2004.
55. Nigeria Pharmaceuticals and Healthcare Report for Q408 (November 2008) – Business Monitor International, at:www.business.monitor.com/pharma/nigeria.html.
56. Ibid.
57. Anon, Guardian Opinion Pool, The Guardian, September 4, 2002.
58. Onuorah, M., “Pool Ranks NAFDAC, EFCC Highest of Government Agencies”, The Guardian, February 19, 2008.